Sigma Labs Inc (SASI)

[RiskReward1]

This is pure CEO applying business smarts sort of move, in my view. Before I had heard the explanation about commercial sales focus vs R&D I had read into Morph's not having the latest PR3D that Rice would have wanted Medeira to pay for it. It looked to me -- and continues to -- that Rice wants to hold out the value of PR3D from Morf until whatever potential deal that may be struck is struck, so that Sigma gets the most attractive terms possible, should a deal involving Sigma come together. To park the product with Morf, particularly the latest version, and then wait to see what place there may be in a possible future deal with Morf, and at what cost/contribution Morf invites Sigma to participate, might be a CTO move, but it wouldn't be a CEO move.

Thanks, Z.